Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 81.44
CDXC's Cash-to-Debt is ranked higher than
52% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. CDXC: 81.44 )
Ranked among companies with meaningful Cash-to-Debt only.
CDXC' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.56  Med: 5.53 Max: No Debt
Current: 81.44
0.56
No Debt
Equity-to-Asset 0.78
CDXC's Equity-to-Asset is ranked higher than
69% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. CDXC: 0.78 )
Ranked among companies with meaningful Equity-to-Asset only.
CDXC' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.26  Med: 0.52 Max: 0.86
Current: 0.78
0.26
0.86
Debt-to-Equity 0.01
CDXC's Debt-to-Equity is ranked higher than
98% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 0.28 vs. CDXC: 0.01 )
Ranked among companies with meaningful Debt-to-Equity only.
CDXC' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01  Med: 0.07 Max: 1.42
Current: 0.01
0.01
1.42
Debt-to-EBITDA -0.02
CDXC's Debt-to-EBITDA is ranked lower than
99.99% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 2.04 vs. CDXC: -0.02 )
Ranked among companies with meaningful Debt-to-EBITDA only.
CDXC' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.19  Med: -0.13 Max: -0.02
Current: -0.02
-3.19
-0.02
Piotroski F-Score: 3
Altman Z-Score: 10.65
Beneish M-Score: -3.27
WACC vs ROIC
8.73%
-305.25%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -98.42
CDXC's Operating Margin % is ranked higher than
53% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. CDXC: -98.42 )
Ranked among companies with meaningful Operating Margin % only.
CDXC' s Operating Margin % Range Over the Past 10 Years
Min: -100.22  Med: -38.3 Max: -11.55
Current: -98.42
-100.22
-11.55
Net Margin % -82.82
CDXC's Net Margin % is ranked higher than
55% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. CDXC: -82.82 )
Ranked among companies with meaningful Net Margin % only.
CDXC' s Net Margin % Range Over the Past 10 Years
Min: -100.45  Med: -39.35 Max: -13.51
Current: -82.82
-100.45
-13.51
ROE % -57.81
CDXC's ROE % is ranked lower than
56% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. CDXC: -57.81 )
Ranked among companies with meaningful ROE % only.
CDXC' s ROE % Range Over the Past 10 Years
Min: -355.87  Med: -80.06 Max: -35.66
Current: -57.81
-355.87
-35.66
ROA % -46.91
CDXC's ROA % is ranked lower than
56% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. CDXC: -46.91 )
Ranked among companies with meaningful ROA % only.
CDXC' s ROA % Range Over the Past 10 Years
Min: -152.39  Med: -44.9 Max: -15.21
Current: -46.91
-152.39
-15.21
ROC (Joel Greenblatt) % -409.52
CDXC's ROC (Joel Greenblatt) % is ranked higher than
57% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. CDXC: -409.52 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CDXC' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -409.52  Med: -202.16 Max: -47.6
Current: -409.52
-409.52
-47.6
3-Year Revenue Growth Rate 3.20
CDXC's 3-Year Revenue Growth Rate is ranked higher than
54% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. CDXC: 3.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CDXC' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -3.05 Max: 24
Current: 3.2
0
24
3-Year EBITDA Growth Rate -33.60
CDXC's 3-Year EBITDA Growth Rate is ranked lower than
82% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. CDXC: -33.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CDXC' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -143.4  Med: -14.6 Max: 48.6
Current: -33.6
-143.4
48.6
3-Year EPS without NRI Growth Rate -35.10
CDXC's 3-Year EPS without NRI Growth Rate is ranked lower than
86% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. CDXC: -35.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CDXC' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -146.6  Med: -9.85 Max: 43.6
Current: -35.1
-146.6
43.6
GuruFocus has detected 2 Warning Signs with ChromaDex Corp CDXC.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CDXC's 30-Y Financials

Financials (Next Earnings Date: 2018-11-10 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

CDXC Guru Trades in

CDXC Guru Trades in

Q4 2017

CDXC Guru Trades in Q4 2017

Jim Simons 45,100 sh (New)
» More
Q1 2018

CDXC Guru Trades in Q1 2018

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CDXC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

ChromaDex Corp does not have enough historical financial data to display Peter Lynch Chart.

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325411    SIC: 2833
Compare:NAS:FBIO, ROCO:4152, TSX:NEPT, XKRX:217730, ROCO:6497, OTCPK:MRMD, NAS:VSTM, NAS:CDMO, TSE:2395, ASX:BNO, NAS:VCYT, ROCO:6471, ASX:MVF, NAS:VBIV, XPAR:TNG, TPE:1720, NAS:CALA, NAS:MLNT, HKSE:01035, XBRU:THR » details
Traded in other countries:OCD1.Germany,
Headquarter Location:USA
ChromaDex Corp is a natural products company. The company discovers, acquires, develops and commercializes patented and proprietary ingredient technologies that address the dietary supplement, food, beverage, skincare and pharmaceutical markets.

ChromaDex Corp is a natural products company. The company discovers, acquires, develops and commercializes patented and proprietary ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. Its product and service portfolio consists of proprietary ingredients, analytical and chemistry based services, regulatory consulting services and natural product fine chemicals. It is organized into three segments: Ingredients, Core Standards, and Contract Services, Scientific and Regulatory Consulting segment.

Ratios

vs
industry
vs
history
PB Ratio 6.25
CDXC's PB Ratio is ranked lower than
59% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. CDXC: 6.25 )
Ranked among companies with meaningful PB Ratio only.
CDXC' s PB Ratio Range Over the Past 10 Years
Min: 2.46  Med: 14.21 Max: 69.44
Current: 6.25
2.46
69.44
PS Ratio 8.60
CDXC's PS Ratio is ranked higher than
56% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CDXC: 8.60 )
Ranked among companies with meaningful PS Ratio only.
CDXC' s PS Ratio Range Over the Past 10 Years
Min: 1.19  Med: 7.13 Max: 103.45
Current: 8.6
1.19
103.45
EV-to-EBIT -8.04
CDXC's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. CDXC: -8.04 )
Ranked among companies with meaningful EV-to-EBIT only.
CDXC' s EV-to-EBIT Range Over the Past 10 Years
Min: -1392.4  Med: -21.55 Max: -2.2
Current: -8.04
-1392.4
-2.2
EV-to-EBITDA -8.26
CDXC's EV-to-EBITDA is ranked lower than
99.99% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. CDXC: -8.26 )
Ranked among companies with meaningful EV-to-EBITDA only.
CDXC' s EV-to-EBITDA Range Over the Past 10 Years
Min: -557.8  Med: -22.7 Max: 960
Current: -8.26
-557.8
960
EV-to-Revenue 7.91
CDXC's EV-to-Revenue is ranked higher than
61% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. CDXC: 7.91 )
Ranked among companies with meaningful EV-to-Revenue only.
CDXC' s EV-to-Revenue Range Over the Past 10 Years
Min: 1  Med: 7.45 Max: 102.2
Current: 7.91
1
102.2
Current Ratio 4.24
CDXC's Current Ratio is ranked higher than
56% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. CDXC: 4.24 )
Ranked among companies with meaningful Current Ratio only.
CDXC' s Current Ratio Range Over the Past 10 Years
Min: 0.33  Med: 2.04 Max: 11
Current: 4.24
0.33
11
Quick Ratio 3.65
CDXC's Quick Ratio is ranked higher than
55% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. CDXC: 3.65 )
Ranked among companies with meaningful Quick Ratio only.
CDXC' s Quick Ratio Range Over the Past 10 Years
Min: 0.33  Med: 1.22 Max: 11
Current: 3.65
0.33
11
Days Inventory 162.85
CDXC's Days Inventory is ranked lower than
69% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: 125.55 vs. CDXC: 162.85 )
Ranked among companies with meaningful Days Inventory only.
CDXC' s Days Inventory Range Over the Past 10 Years
Min: 39.68  Med: 149.31 Max: 260.41
Current: 162.85
39.68
260.41
Days Sales Outstanding 66.91
CDXC's Days Sales Outstanding is ranked lower than
53% of the 668 Companies
in the Global Biotechnology industry.

( Industry Median: 64.17 vs. CDXC: 66.91 )
Ranked among companies with meaningful Days Sales Outstanding only.
CDXC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 28.27  Med: 46.9 Max: 98.59
Current: 66.91
28.27
98.59
Days Payable 173.05
CDXC's Days Payable is ranked higher than
73% of the 536 Companies
in the Global Biotechnology industry.

( Industry Median: 63.91 vs. CDXC: 173.05 )
Ranked among companies with meaningful Days Payable only.
CDXC' s Days Payable Range Over the Past 10 Years
Min: 40.67  Med: 126.35 Max: 219.49
Current: 173.05
40.67
219.49

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -15.30
CDXC's 3-Year Average Share Buyback Ratio is ranked lower than
55% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. CDXC: -15.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CDXC' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -55.3  Med: -17.75 Max: -2.5
Current: -15.3
-55.3
-2.5

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 11.55
CDXC's Price-to-Net-Cash is ranked lower than
55% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 7.29 vs. CDXC: 11.55 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CDXC' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 7.64  Med: 27.27 Max: 158
Current: 11.55
7.64
158
Price-to-Net-Current-Asset-Value 7.33
CDXC's Price-to-Net-Current-Asset-Value is ranked higher than
54% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: 6.45 vs. CDXC: 7.33 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CDXC' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 5.53  Med: 28.27 Max: 562.5
Current: 7.33
5.53
562.5
Price-to-Tangible-Book 6.51
CDXC's Price-to-Tangible-Book is ranked lower than
51% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 5.32 vs. CDXC: 6.51 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CDXC' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 5.11  Med: 16.93 Max: 66.18
Current: 6.51
5.11
66.18
Price-to-Median-PS-Value 1.21
CDXC's Price-to-Median-PS-Value is ranked lower than
65% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. CDXC: 1.21 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CDXC' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.17  Med: 0.97 Max: 10.92
Current: 1.21
0.17
10.92
Earnings Yield (Greenblatt) % -12.44
CDXC's Earnings Yield (Greenblatt) % is ranked lower than
56% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. CDXC: -12.44 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CDXC' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -44.8  Med: -4.65 Max: -0.1
Current: -12.44
-44.8
-0.1

More Statistics

Revenue (TTM) (Mil) $27.99
EPS (TTM) $ -0.46
Beta0.97
Volatility91.54%
52-Week Range $3.12 - 7.24
Shares Outstanding (Mil)55.06

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 33 65 100
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) -0.53 -0.03 0.27
EPS without NRI ($) -0.53 -0.03 0.27
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}